Seizure News and Research

Latest Seizure News and Research

Researchers decode words from brain signals in paralyzed people

In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain. "We have been able to decode spoken words using only signals from the brain with a device that has promise for long-term use in paralyzed patients who cannot now speak," says Bradley Greger, an assistant professor of bioengineering.

7 Sep 2010

ISWG researchers establish guidelines for diagnosis and treatment of infantile spasms

Researchers from across the U.S., as part of the Infantile Spasms Working Group (ISWG), established guidelines for the diagnosis and treatment of infantile spasms (IS). The goal of the ISWG is to improve patient outcomes by creating protocols that educate pediatricians on early diagnosis and treatment options. Full details of this study appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

3 Sep 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Researchers examine functions of neuronal diversity

Much like snowflakes, no two neurons are exactly alike. But it's not the size or shape that sets one neuron apart from another, it's the way it responds to incoming stimuli. Carnegie Mellon University researchers have discovered that this diversity is critical to overall brain function and essential in how neurons process complex stimuli and code information.

30 Aug 2010

New high throughput sequencing technology to identify genetic defects in rare diseases

The majority of rare diseases are hereditary. But despite significant progress in genome research, in most cases their exact cause remains unclear. The discovery of the underlying genetic defect is, however, a prerequisite for their definitive diagnosis and the development of innovative approaches to their treatment. Scientists at the Max Planck Institute for Molecular Genetics and the Institute of Medical Genetics at the Charit- Universit-tsmedizin - Berlin have succeeded in using a new process with which all of the genes in the human genome can be analysed simultaneously.

30 Aug 2010

Authorities arrest more than 80 people, seize 10 tons of counterfeit meds in E. Africa

Authorities have arrested more than 80 people and seized 10 tons of counterfeit medicines across six East African countries, the international police agency Interpol announced Thursday, United Press International reports (8/26).

27 Aug 2010

Researchers find two high-fat diets reduce absence epilepsy in children

Two high-fat diets the classic ketogenic and a modified version of the Atkins can reduce and, in some cases, completely eliminate seizures in children with a common seizure disorder known as absence epilepsy, say researchers from Johns Hopkins Children's Center.

27 Aug 2010

Increasing levels of neuropeptide Y, receptors can counteract seizures: Research

Research in recent years has shown that the brain tries to counteract seizures. One of the ways it does this is by increasing levels of a protein-like molecule called neuropeptide Y and the expression of certain receptors for it.

25 Aug 2010

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.

25 Aug 2010

Cyberonics enters agreement with NeuroVista for epilepsy technology development program

Cyberonics, Inc. today announced that it has entered into additional agreements with NeuroVista Corporation in the field of EEG-based seizure detection to build on its position as the leader in medical devices for epilepsy.

25 Aug 2010

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of its New Therapy Grants Program, a unique joint venture of the non-profit epilepsy organizations, to advance promising epilepsy research in clinical development. The grant awards, totaling approximately $200,000 in funding, will support an experimental gene therapy that directly targets epileptogenic brain tissue, as well as an electrode system that has the potential to improve the efficacy of surgical therapies for certain epilepsy syndromes.

24 Aug 2010

Scientists suggest combination vaccine prevents pertussis

If you think you shouldn't be worried about your child's—or your—lingering, nagging cough, think again. Pertussis has reemerged on the scene. In what some public health officials are calling the worst outbreak in 50 years, pertussis, better known by its unique sound—whooping cough, has been found in six states with 1,500 cases reported, six of them fatal.

19 Aug 2010

Lamictal can cause aseptic meningitis: FDA

The U.S. Food and Drug Administration today warned that the drug Lamictal (lamotrigine), approved to treat seizures and bipolar disorder, can cause aseptic meningitis, an inflammation of the protective membranes (meninges) that cover the brain and spinal cord not caused by bacterial infection.The agency is working with the drug's manufacturer, GlaxoSmithKline, to update the prescribing information and patient medication guide to include this risk.

13 Aug 2010

FDA advisory committee votes in favor of Ezogabine

The U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of Ezogabine (known as Retigabine outside of the U.S.) as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Study finds selective serotonin reuptake inhibitors not beneficial for autistic children

Antidepressants commonly prescribed to people with autistic spectrum disorders cannot be recommended based on current evidence, a new study by Cochrane Researchers concludes. Despite some evidence of benefits in adults diagnosed with autism, they say there is no evidence for any benefits associated with selective serotonin reuptake inhibitors (SSRIs) in children, who may suffer serious adverse effects as a result of taking the drugs.

9 Aug 2010

Antidepressants cannot be recommended in children with autism: Study

According to a thorough review published by Cochrane Researchers, commonly prescribed antidepressant drugs cannot be recommended for those suffering from autistic spectrum disorders based on current evidence. They say that there may be benefits of antidepressants in adults diagnosed with autism but similar benefits are not seen in children. These children may suffer extremely adverse effects if they consume selective serotonin reuptake inhibitors (SSRIs).

8 Aug 2010

Long-term exposure to valproate leads to bone loss: Study

Scientists are reporting a possible explanation for the bone loss that may occur following long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. The drug, valproate, appears to reduce the formation of two key proteins important for bone strength, they said. Their study, which offers a solution to a long-standing mystery, appears in ACS' monthly Journal of Proteome Research.

5 Aug 2010

EEG patterns can predict schizophrenia patients' response to clozapine therapy

A commonplace electroencephalography (EEG) test may hold the key to predicting whether a person will respond to certain prescribed drugs, particularly those related to psychiatric conditions.In a study to be published by Clinical Neurophysiology, and now posted online, engineering and health sciences researchers at McMaster University applied machine learning to EEG patterns and successfully predicted how patients with schizophrenia would respond to clozapine therapy.

5 Aug 2010

Seizure News and Research

Latest Seizure News and Research

Researchers decode words from brain signals in paralyzed people

ISWG researchers establish guidelines for diagnosis and treatment of infantile spasms

FDA extends Prescription Drug User Fee Act date for ezogabine

Researchers examine functions of neuronal diversity

New high throughput sequencing technology to identify genetic defects in rare diseases

Authorities arrest more than 80 people, seize 10 tons of counterfeit meds in E. Africa

Researchers find two high-fat diets reduce absence epilepsy in children

Increasing levels of neuropeptide Y, receptors can counteract seizures: Research

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

Cyberonics enters agreement with NeuroVista for epilepsy technology development program

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

Scientists suggest combination vaccine prevents pertussis

Lamictal can cause aseptic meningitis: FDA

FDA advisory committee votes in favor of Ezogabine

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Study finds selective serotonin reuptake inhibitors not beneficial for autistic children

Antidepressants cannot be recommended in children with autism: Study

Long-term exposure to valproate leads to bone loss: Study

EEG patterns can predict schizophrenia patients' response to clozapine therapy

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Seizure News and Research

Latest Seizure News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in